William C Reinhold
Overview
Explore the profile of William C Reinhold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
4484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reinhold W, Marangoni E, Elloumi F, Montagne R, Varma S, Wang Y, et al.
Cancer Res Commun
. 2025 Feb;
5(2):375-388.
PMID: 39932272
Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy...
2.
Fan W, Liu H, Stachelek G, Begum A, Davis C, Dorado T, et al.
bioRxiv
. 2024 Aug;
PMID: 39211199
Ribosome biosynthesis is a cancer vulnerability executed by targeting RNA polymerase I (Pol I) transcription. We developed advanced, specific Pol I inhibitors to identify drivers of this sensitivity. By integrating...
3.
Arakawa Y, Elloumi F, Varma S, Khandagale P, Jo U, Kumar S, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2384-2398.
PMID: 39162009
Significance: ACC_CellMinerCDB, a comprehensive database of cell lines, patient-derived xenografts, surgical samples, and drug responses, reveals shared genomic pathways and treatment-relevant markers in ACC. This resource offers insights into potential...
4.
Mizunuma M, Redon C, Saha L, Tran A, Dhall A, Sebastian R, et al.
Cancer Res Commun
. 2024 Jul;
4(8):2101-2111.
PMID: 39041239
Significance: Acetalax and bisacodyl kill cancer cells by causing oncosis following poisoning of the plasma membrane sodium transporter TRPM4 and represent a new therapeutic approach for TNBC.
5.
Tlemsani C, Heske C, Elloumi F, Pongor L, Khandagale P, Varma S, et al.
iScience
. 2024 Jun;
27(6):109781.
PMID: 38868205
Sarcomas are a diverse group of rare malignancies composed of multiple different clinical and molecular subtypes. Due to their rarity and heterogeneity, basic, translational, and clinical research in sarcoma has...
6.
Sun R, Ge W, Zhu Y, Sayad A, Luna A, Lyu M, et al.
Mol Cell Proteomics
. 2023 Jun;
22(8):100602.
PMID: 37343696
Treatment and relevant targets for breast cancer (BC) remain limited, especially for triple-negative BC (TNBC). We identified 6091 proteins of 76 human BC cell lines using data-independent acquisition (DIA). Integrating...
7.
Reinhold W, Wilson K, Elloumi F, Bradwell K, Ceribelli M, Varma S, et al.
Cancer Res
. 2023 May;
83(12):1941-1952.
PMID: 37140427
Significance: CellMinerCDB: NCATS provides activity information for 2,675 drugs in 183 cancer cell lines and analysis tools to facilitate pharmacogenomic research and to identify determinants of response.
8.
Safari M, Litman T, Robey R, Aguilera A, Chakraborty A, Reinhold W, et al.
Mol Cancer Res
. 2021 May;
19(8):1361-1374.
PMID: 34050002
Histone deacetylase inhibitors (HDACi) induce hyperacetylation of histones by blocking HDAC catalytic sites. Despite regulatory approvals in hematological malignancies, limited solid tumor clinical activity has constrained their potential, arguing for...
9.
Vural S, Palmisano A, Reinhold W, Pommier Y, Teicher B, Krushkal J
Clin Epigenetics
. 2021 Mar;
13(1):49.
PMID: 33676569
Background: Altered DNA methylation patterns play important roles in cancer development and progression. We examined whether expression levels of genes directly or indirectly involved in DNA methylation and demethylation may...
10.
Luna A, Elloumi F, Varma S, Wang Y, Rajapakse V, Aladjem M, et al.
Nucleic Acids Res
. 2020 Nov;
49(D1):D1083-D1093.
PMID: 33196823
CellMiner Cross-Database (CellMinerCDB, discover.nci.nih.gov/cellminercdb) allows integration and analysis of molecular and pharmacological data within and across cancer cell line datasets from the National Cancer Institute (NCI), Broad Institute, Sanger/MGH and...